Leap Therapeutics Stock Forecast, Price & News

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

Is Leap Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Leap Therapeutics stock.
View analyst ratings for Leap Therapeutics or view top-rated stocks.

How has Leap Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LPTX stock has increased by 26.4% and is now trading at $2.54.
View which stocks have been most impacted by COVID-19.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 11th 2022.
View our earnings forecast for Leap Therapeutics.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its earnings results on Friday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. Leap Therapeutics had a negative net margin of 2,433.93% and a negative trailing twelve-month return on equity of 63.02%.
View Leap Therapeutics' earnings history.

What price target have analysts set for LPTX?

4 brokerages have issued 12 month price objectives for Leap Therapeutics' shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate Leap Therapeutics' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 77.2% from the stock's current price.
View analysts' price targets for Leap Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:

• Doug E. Onsi, President, CEO, CFO, Secretary & Treasurer
• Augustine J. Lawlor, Chief Operating Officer
• Cynthia Sirard, Chief Medical Officer
• Michael Haas, Head-Research
• Jason S. Baum, Vice President & Head-Translational Medicine

Who are some of Leap Therapeutics' key competitors?

Some companies that are related to Leap Therapeutics include BELLUS Health (BLUSF), Seres Therapeutics (MCRB), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Olema Pharmaceuticals (OLMA), Arcutis Biotherapeutics (ARQT), Kinnate Biopharma (KNTE), ADVANZ PHARMA (CXRXF), Celularity (CELU), Gossamer Bio (GOSS), Syndax Pharmaceuticals (SNDX), Kiniksa Pharmaceuticals (KNSA), Precigen (PGEN), CytoDyn (CYDY) and Imago BioSciences (IMGO).
View all of LPTX's competitors.

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL).

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Artal Group S.A. (6.70%), Deerfield Management Company L.P. Series C (6.70%), Rock Springs Capital Management LP (5.88%), Tang Capital Management LLC (4.19%), Tri Locum Partners LP (3.03%) and Platinum Investment Management Ltd. (2.22%).
View institutional ownership trends for Leap Therapeutics.

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., BlackRock Inc., Citadel Advisors LLC, and McAdam LLC.
View insider buying and selling activity for Leap Therapeutics or view top insider-selling stocks.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Rock Springs Capital Management LP, Tang Capital Management LLC, Tri Locum Partners LP, Artal Group S.A., Renaissance Technologies LLC, EAM Investors LLC, and EAM Global Investors LLC.
View insider buying and selling activity for Leap Therapeutics or or view top insider-buying stocks.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.54.

How much money does Leap Therapeutics make?

Leap Therapeutics has a market capitalization of $224.33 million and generates $1.50 million in revenue each year. The company earns $-27.51 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Leap Therapeutics have?

Leap Therapeutics employs 30 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is www.leaptx.com.

Where are Leap Therapeutics' headquarters?

Leap Therapeutics is headquartered at 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at (617) 714-0360 or via email at [email protected].